Skip Nav Destination
Issues
1 March 2019
-
Cover Image
Cover Image
About the Cover
Cytotoxic T lymphocytes (CTLs) play a key role in antitumor immunity, and the function of these cells can be suppressed in the tumor microenvironment (TME). Lu et al. show how epigenetic states in the TME suppress effector functions and can be countered by small molecule–targeted therapy in colon cancer. CTLs infiltrate tumors and have high expression of the histone methyltransferase SUV39H1, which decorates the histone H3K9me3. H3K9me3 is enriched in the promoter region of several key CTL effector genes and suppressed their expression. By specifically targeting SUV39H1 with a small-molecule inhibitor, called F5446, expression of the effector genes is enhanced, and the antitumor function of CTLs in the tumor microenvironment is increased. Read more in this issue on page 414. Original image from Fig. 1. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2326-6066
EISSN 2326-6074
Journal Archive
Cancer Immunology Research (2013-Present)
(ISSN 2326-6066) Published monthly since 2013.Cancer Immunity (2001-2013; volumes 1-13)
(EISSN 1424-9634) Published periodically from 2001-2013.Table of Contents
What We’re Reading
Cancer Immunology at the Crossroads
Priority Brief
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Sarah E. Josefsson; Klaus Beiske; Yngvild N. Blaker; Mette S. Førsund; Harald Holte; Bjørn Østenstad; Eva Kimby; Hakan Köksal; Sébastien Wälchli; Baoyan Bai; Erlend B. Smeland; Ronald Levy; Arne Kolstad; Kanutte Huse; June H. Myklebust
Research Articles
CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance
Michele Mondini; Pierre-Louis Loyher; Pauline Hamon; Marine Gerbé de Thoré; Marie Laviron; Kevin Berthelot; Céline Clémenson; Benoit L. Salomon; Christophe Combadière; Eric Deutsch; Alexandre Boissonnas
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion
Chunwan Lu; Dafeng Yang; John D. Klement; Il Kyu Oh; Natasha M. Savage; Jennifer L. Waller; Aaron H. Colby; Mark W. Grinstaff; Nicholas H. Oberlies; Cedric J. Pearce; Zhiliang Xie; Samuel K. Kulp; Christopher C. Coss; Mitch A. Phelps; Thomas Albers; Iryna O. Lebedyeva; Kebin Liu
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity
Hayley S. Ma; Bibhav Poudel; Evanthia Roussos Torres; John-William Sidhom; Tara M. Robinson; Brian Christmas; Blake Scott; Kayla Cruz; Skylar Woolman; Valerie Z. Wall; Todd Armstrong; Elizabeth M. Jaffee
Author Choice
IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation
Pamela Caudana; Nicolas Gonzalo Núñez; Philippe De La Rochere; Anaïs Pinto; Jordan Denizeau; Ruby Alonso; Leticia Laura Niborski; Olivier Lantz; Christine Sedlik; Eliane Piaggio
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma
Erik Yusko; Marissa Vignali; Richard K. Wilson; Elaine R. Mardis; F. Stephen Hodi; Christine Horak; Han Chang; David M. Woods; Harlan Robins; Jeffrey Weber
Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer
Robert S. Svatek; Niannian Ji; Essel de Leon; Neelam Z. Mukherjee; Aashish Kabra; Vincent Hurez; Marlo Nicolas; Joel E. Michalek; Martin Javors; Karen Wheeler; Z. Dave Sharp; Carolina B. Livi; Zhen-Ju Shu; David Henkes; Tyler J. Curiel
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.